(R)-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-6-oxo-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-3-carboxamide | 1088714-15-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (R)-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-6-oxo-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-3-carboxamide
• 英文别名: N-[(2R)-2,3-dihydroxypropoxy]-2-(2-fluoro-4-iodoanilino)-1-methyl-6-oxo-4,5-dihydrocyclopenta[b]pyrrole-3-carboxamide
• CAS: 1088714-15-1
• 化学式: C₁₈H₁₉FIN₃O₅
• 分子量: 503.269
• InChiKey: AFXDUYNYFWFDSL-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氟-4-碘苯胺 在 水 、 碳酸氢钠 、 1-羟基苯并三唑 、 caesium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-N-(2,3-dihydroxypropoxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-6-oxo-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-3-carboxamide
  参考文献：
  名称：

  Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy

  摘要：

  The structure-based design, synthesis, and biological evaluation of two novel series of potent and selective MEK kinase inhibitors are described herein. The elaboration of a lead pyrrole derivative to a bicyclic dihydroindolone core provided compounds with high potency and good drug-like pharmaceutical properties. Further scaffold modification afforded a series of dihydroindolizinone inhibitors, including an orally available advanced preclinical MEK inhibitor with potent in vivo antitumor efficacy. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.026

文献信息

• MAPK/ERK KINASE INHIBITORS
  申请人：Adams Mark E.

  公开号：US20080312307A1

  公开（公告）日：2008-12-18

  Compounds are provided for inhibition of MEK that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供了一些用于抑制MEK的化合物，其中变量的定义如下。此外，还提供了包含这些化合物的药物组合物、工具箱和制造物品；用于制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• WO2008/148034
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] MAPK/ERK KINASE INHIBITORS<br/>[FR] INHIBITEURS DE MAPK/ERK KINASE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2008148034A1

  公开（公告）日：2008-12-04

  [EN] Compounds are provided for inhibition of MEK that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
  [FR] L'invention concerne des composés pour inhiber une MEK qui comprennent les variables telles que définies ici. Des compositions pharmaceutiques, des trousses et des articles de fabrication comprenant de tels composés ; des procédés intermédiaires utiles pour préparer les composés ; et des procédés d'utilisation desdits composés sont également proposés.
• Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy
  作者：Mark E. Adams、Michael B. Wallace、Toufike Kanouni、Nicholas Scorah、Shawn M. O’Connell、Hiroshi Miyake、Lihong Shi、Petro Halkowycz、Lilly Zhang、Qing Dong

  DOI：10.1016/j.bmcl.2012.02.026

  日期：2012.4

  The structure-based design, synthesis, and biological evaluation of two novel series of potent and selective MEK kinase inhibitors are described herein. The elaboration of a lead pyrrole derivative to a bicyclic dihydroindolone core provided compounds with high potency and good drug-like pharmaceutical properties. Further scaffold modification afforded a series of dihydroindolizinone inhibitors, including an orally available advanced preclinical MEK inhibitor with potent in vivo antitumor efficacy. (C) 2012 Elsevier Ltd. All rights reserved.